Disabling immune suppression mediated by a specific type of macrophage may boost the effectiveness of poly ADP ribose polymerase (PARP) inhibitor therapy for some forms of breast cancer, according to research lead by a team of investigators from the Dana-Farber Cancer Institute (DFCI). Reporting in Nature Cancer, the researchers identified…

Cambridge, U.K.-based diagnostic assay developer APIS Assay Technologies announced today a collaboration with the lab of Elsa Flores, Ph.D., and Marco Napoli, Ph.D. at Moffitt Cancer Center to assess the suitability of TROLL-2 and TROLL-3 as predictive biomarkers of cancer progression and their roll as markers of chemotherapy response. Earlier…

Tumor size has a strong impact on survival rates of patients with pancreatic cancer (PC), which are some of the worst of all cancer with a five-year survival rate of only 10%. The larger the tumor, the less likely it is to be cured by resection. There have been cases,…

A discovery of four new cell types in triple negative breast cancer tumors could lead to new and more effective therapies for patients with this cancer, suggest scientists from the Garvan Institute of Medical Research in Australia. The research team used RNA sequencing to analyze gene expression in tumors taken…

A change of protocol for treating breast cancer has yielded positive results for researchers at Yale Cancer Center (YCC). A new study shows women with high-risk HER2-negative breast cancer treated with immunotherapy and then surgery, and given a PARP inhibitor with chemotherapy, have improved treatment results. “The results provide further…

Scientists at the University of Chicago have discovered a new class of drug compounds to potentially treat FOXM1positive breast cancer.  This would be the first known type of drug to treat the FOXM1 mutation, and the new compounds have been shown to suppress tumor growth in preclinical breast tumor models, though…

Triple-negative breast cancers (TNBCs) are particularly aggressive, metastatic and resistant to chemotherapy treatments.  Researchers at the University of Texas MD Anderson Cancer Center have discovered that these cells alter epigenetic programing to temporarily become drug-resistant. The resistant cells switch metabolic pathways from glycolysis to mitochondrial respiration, but a new drug…

The FDA has approved Roche’s VENTANA PD-L1 (SP142) Assay as the first companion diagnostic (CDx) authorized for the combination therapy of Tecentriq® (atezolizumab), marketed by Genentech, a member of the Roche Group, and Celgene’s chemotherapy Abraxane® (paclitaxel protein-bound particles for injectable suspension [albumin-bound]; nab-paclitaxel), Roche said today. Launched in 2016,…

Scientists at The Scripps Research Institute and the California Institute for Biomedical Research (CALIBR) have found that some types of small-molecule drugs, including marketed anticancer drugs, may work in part by binding to disease-related noncoding RNAs. Their discovery could open up new avenues of research for developing small-molecule drugs against…

Scientists at The Scripps Research Institute have developed a small molecule-based RNA-editing tool that can selectively delete RNA targets associated with diseases such as cancer. Offering a potential alternative to CRISPR-Cas9–based tools that edit DNA, the new technology, developed by Matthew D. Disney, Ph.D., attaches an RNA-targeting, drug-like molecule to…

One in eight women will be diagnosed with breast cancer in her lifetime, and one in 30 is expected to die from it. Thus, understanding the underlying molecular mechanisms that cause breast tumors to become metastatic is critical for improved therapies and patient outcomes. Now, investigators at the Montreal Clinical…

Researchers in the department of molecular biology at Princeton University have identified a microRNA (miRNA) that helps maintain the activity of stem cells in both healthy and cancerous breast tissue. The findings of the study “Normal and Cancerous Mammary Stem Cells Evade Interferon-Induced Constraint through the miR-199a–LCOR Axis” to be…

Georgia State University (GSU) researchers have just published new results showing that high levels of a certain biomarker is linked to poor prognosis in African-American patients with triple-negative breast cancer. Researchers are concerned that the dire outcome of this group could indicate that high-risk, African-American breast cancer patients are not…

BETHESDA, Md. – The National Cancer Institute, part of the NIH, has provided a $12 million grant to launch the largest single study ever to help determine how genetic and biological factors contribute to the risk of breast cancer among black women. Dubbed the Breast Cancer Genetic Study in African-Ancestry…

Predicting the prognosis of triple-negative breast cancer (TNBC) could be faster and more accurate using a new xenograft tool developed by scientists at Huntsman Cancer Institute at the University of Utah. TNBC is a particularly aggressive disease.  The team found that, “Only the most aggressive breast cancers can grow in…